ProLectin-M / Bioxytran - LARVOL DELTA

To Evaluate the Safety, Efficacy,and Pharmacokinetics of Orally Administered Prolectin-M (clinicaltrials.gov) - P1b/2a | N=40 | Not yet recruiting | Sponsor: Bioxytran Inc. | Trial completion date: Jun 2023 ➔ Feb 2024 | Initiation date: Apr 2023 ➔ Sep 2023 | Trial primary completion date: Jun 2023 ➔ Dec 2023

Trial completion date • Trial initiation date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Bioxytran Announces FDA Clearance of its IND Application for ProLectin-M in Clinical Trials (GlobeNewswire) - "BIOXYTRAN, INC...announced that it has received clearance of its Investigational New Drug (IND) application from the U.S. Food and Drug Administration (FDA), to initiate clinical trials of ProLectin-M for the treatment of mild to moderate COVID-19 in standard risk patients."

IND • Infectious Disease • Novel Coronavirus Disease

An Oral Galectin Inhibitor in COVID-19-A Phase II Randomized Controlled Trial. (PubMed, Vaccines (Basel)) - "PL-M is safe and effective for clinical use in reducing viral loads and promoting rapid viral clearance in COVID-19 patients by inhibiting SARS-CoV-2 entry into cells through the inhibition of Gal-3."

Clinical • Journal • P2 data • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • LGALS3

To Evaluate the Safety, Efficacy,and Pharmacokinetics of Orally Administered Prolectin-M (clinicaltrials.gov) - P1b/2a | N=40 | Not yet recruiting | Sponsor: Bioxytran Inc. | Trial completion date: Mar 2023 ➔ Jun 2023 | Trial primary completion date: Feb 2023 ➔ Jun 2023

Trial completion date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases